Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
5.87
-0.09 (-1.51%)
At close: Nov 14, 2025, 4:00 PM EST
6.10
+0.23 (3.92%)
After-hours: Nov 14, 2025, 5:21 PM EST
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $3.56M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $3.99M, down -58.26% year-over-year. In the year 2024, Coya Therapeutics had annual revenue of $3.55M, down -40.79%.
Revenue (ttm)
$3.99M
Revenue Growth
-58.26%
P/S Ratio
24.49
Revenue / Employee
$498,463
Employees
8
Market Cap
98.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.55M | -2.45M | -40.79% |
| Dec 31, 2023 | 6.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
COYA News
- 3 days ago - Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update - Business Wire
- 11 days ago - Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo - Business Wire
- 18 days ago - Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares - Business Wire
- 22 days ago - Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock - Business Wire
- 22 days ago - Coya Therapeutics Announces Proposed Public Offering of Common Stock - Business Wire
- 5 weeks ago - Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function - Business Wire
- 6 weeks ago - Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia - PRNewsWire
- 7 weeks ago - Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis - PRNewsWire